Compile Data Set for Download or QSAR
Report error Found 149 Enz. Inhib. hit(s) with all data for entry = 11711
TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642333(US20230406840, Example 11)
Affinity DataKd:  17nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642334(US20230406840, Example 12)
Affinity DataKd:  13nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642338(US20230406840, Example 16)
Affinity DataKd:  20nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642341(US20230406840, Example 17)
Affinity DataKd:  8.5nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642347(US20230406840, Example 21)
Affinity DataKd:  10nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642350(US20230406840, Example 24)
Affinity DataKd:  8.20nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642354(US20230406840, Example 28)
Affinity DataKd:  7.80nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642355(US20230406840, Example 29)
Affinity DataKd:  11nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642362(US20230406840, Example 36)
Affinity DataKd:  4.30nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642366(US20230406840, Example 40)
Affinity DataKd:  5.5nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642369(US20230406840, Example 43)
Affinity DataKd:  11nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642370(US20230406840, Example 44)
Affinity DataKd:  12nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642371(US20230406840, Example 45)
Affinity DataKd:  7.30nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642372(US20230406840, Example 46)
Affinity DataKd:  25nMAssay Description:Table 1B: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hF...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642361(US20230406840, Example 35)
Affinity DataIC50: 0.0970nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642323(US20230406840, Example 3)
Affinity DataIC50: 0.120nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642366(US20230406840, Example 40)
Affinity DataIC50: 0.150nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642322(US20230406840, Example 2)
Affinity DataIC50: 0.180nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642372(US20230406840, Example 46)
Affinity DataIC50: 0.180nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642371(US20230406840, Example 45)
Affinity DataIC50: 0.25nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642350(US20230406840, Example 24)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642355(US20230406840, Example 29)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642363(US20230406840, Example 37)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642349(US20230406840, Example 23)
Affinity DataIC50: 0.330nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642351(US20230406840, Example 25)
Affinity DataIC50: 0.370nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642341(US20230406840, Example 17)
Affinity DataIC50: 0.380nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642333(US20230406840, Example 11)
Affinity DataIC50: 0.400nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642356(US20230406840, Example 30)
Affinity DataIC50: 0.410nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642365(US20230406840, Example 39)
Affinity DataIC50: 0.410nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642321(6-Bromo-N-(2-((1S,3S,5S)-3-cyano-2-azabicyclo[3.1....)
Affinity DataIC50: 0.440nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642346(US20230406840, Example 20)
Affinity DataIC50: 0.480nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642366(US20230406840, Example 40)
Affinity DataIC50: 0.490nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642348(US20230406840, Example 22)
Affinity DataIC50: 0.510nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642331(US20230406840, Example 9)
Affinity DataIC50: 0.560nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642369(US20230406840, Example 43)
Affinity DataIC50: 0.560nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642362(US20230406840, Example 36)
Affinity DataIC50: 0.580nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642361(US20230406840, Example 35)
Affinity DataIC50: 0.640nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642322(US20230406840, Example 2)
Affinity DataIC50: 0.650nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642323(US20230406840, Example 3)
Affinity DataIC50: 0.680nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642352(US20230406840, Example 26)
Affinity DataIC50: 0.700nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642334(US20230406840, Example 12)
Affinity DataIC50: 0.75nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642371(US20230406840, Example 45)
Affinity DataIC50: 0.760nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642338(US20230406840, Example 16)
Affinity DataIC50: 0.810nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642349(US20230406840, Example 23)
Affinity DataIC50: 0.810nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642335(US20230406840, Example 13)
Affinity DataIC50: 0.860nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642336(US20230406840, Example 14)
Affinity DataIC50: 0.910nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642347(US20230406840, Example 21)
Affinity DataIC50: 0.970nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642337(US20230406840, Example 15)
Affinity DataIC50: 1.10nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642370(US20230406840, Example 44)
Affinity DataIC50: 1.10nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM642350(US20230406840, Example 24)
Affinity DataIC50: 1.20nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 149 total ) | Next | Last >>
Jump to: